lansoprazole and 6 beta-hydroxycortisol

lansoprazole has been researched along with 6 beta-hydroxycortisol in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (50.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL	1
Fuchs, W; Klotz, U; Sennewald, R	1
Mansmann, U; Roots, I; Rost, KL	1
Echizen, H; Nachi, S; Ohnishi, A; Ushiama, H	1

Trials

3 trial(s) available for lansoprazole and 6 beta-hydroxycortisol

Article	Year
Lansoprazole does not affect the bioavailability of oral contraceptives. British journal of clinical pharmacology, 1994, Volume: 38, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Biological Availability; Chromatography, High Pressure Liquid; Contraceptives, Oral; Cross-Over Studies; Estradiol; Ethinyl Estradiol; Female; Follicle Stimulating Hormone; Glucaric Acid; Humans; Hydrocortisone; Lansoprazole; Levonorgestrel; Luteinizing Hormone; Menstrual Cycle; Omeprazole; Progesterone; Proton Pump Inhibitors; Sex Hormone-Binding Globulin; Therapeutic Equivalency	1994
Urinary 6 beta-hydroxycortisol and D-glucaric acid excretion rates are not affected by lansoprazole treatment. International journal of clinical pharmacology and therapeutics, 1997, Volume: 35, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Contraceptives, Oral, Combined; Cross-Over Studies; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Estradiol Congeners; Ethinyl Estradiol; Female; Glucaric Acid; Humans; Hydrocortisone; Lansoprazole; Levonorgestrel; Omeprazole; Placebos; Progesterone Congeners	1997
Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. Clinical pharmacology and therapeutics, 2002, Volume: 72, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hydrocortisone; Lansoprazole; Liver Function Tests; Male; Middle Aged; Omeprazole; Oxidoreductases, N-Demethylating; Penicillins; Protein Synthesis Inhibitors	2002

Other Studies

1 other study(ies) available for lansoprazole and 6 beta-hydroxycortisol

Article	Year
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics. PloS one, 2016, Volume: 11, Issue:10 Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat	2016

Article

Year

Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.

PloS one, 2016, Volume: 11, Issue:10

Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat

2016